SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users ...
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary ...
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
DexCom Inc. DXCM recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for ...
Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform daily metabolic health management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results